- Trials with a EudraCT protocol (173)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
173 result(s) found for: Arterial oxygen saturation.
Displaying page 9 of 9.
EudraCT Number: 2010-024332-42 | Sponsor Protocol Number: BAY63-2521/13605 | Start Date*: 2014-04-10 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled phase II study to investigate the efficacy and safety of riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in patients with symptomatic pulmon... | |||||||||||||
Medical condition: pulmonary hypertension associated with idiopathic interstitial pneumonias | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) DE (Completed) ES (Completed) BE (Completed) GB (Completed) PT (Completed) DK (Completed) GR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000658-27 | Sponsor Protocol Number: D5130C05262 | Start Date*: 2006-12-12 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute C... | |||||||||||||
Medical condition: non-ST and ST elevation acute coronary syndromes (ACS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) FI (Completed) PT (Completed) HU (Completed) DE (Completed) FR (Completed) SE (Completed) AT (Completed) NL (Completed) DK (Completed) SK (Completed) BE (Completed) CZ (Completed) GR (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001246-26 | Sponsor Protocol Number: W-4873-201 | Start Date*: 2016-10-07 | |||||||||||
Sponsor Name:Wockhardt Bio AG | |||||||||||||
Full Title: A Phase II, Randomized, Double-Blind, Multicenter, Comparative Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Oral Nafithromycin Versus Oral Moxifloxacin in the Treat... | |||||||||||||
Medical condition: Community-Acquired Bacterial Pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002726-39 | Sponsor Protocol Number: D4910C00009/C3601001 | Start Date*: 2016-02-25 |
Sponsor Name:Pfizer Inc. | ||
Full Title: A Phase IIa prospective, open-label, multicenter study to determine the pharmacokinetics (PK) and safety and tolerability of aztreonam-avibactam (ATM-AVI) for the treatment of complicated Intra-Abd... | ||
Medical condition: Complicated Intra-Abdominal Infections (cIAIs) in hospitalized adults | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-000467-24 | Sponsor Protocol Number: ALN-TTR02-002 | Start Date*: 2012-05-08 | ||||||||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Phase 2, Open-Label, Multi-Dose, Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Infusions of ALN-TTR02 in Patients with TTR Amyl... | ||||||||||||||||||
Medical condition: Transthyretin mediated amyloidosis (ATTR) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Completed) PT (Completed) DE (Completed) ES (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-003409-23 | Sponsor Protocol Number: MERMAID1 | Start Date*: 2023-12-12 | |||||||||||
Sponsor Name:Medical University of Warsaw | |||||||||||||
Full Title: Application of antiCD19 CAR T lymphocytes for the treatment of adult patients with B-cell acute lymphoblastic leukemia. with resistance, relapse or detectable measurable residual disease. Phase I/I... | |||||||||||||
Medical condition: B-cell acute lymphoblastic leukemia. with resistance, relapse or detectable measurable residual disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001159-11 | Sponsor Protocol Number: POL7080-010 | Start Date*: 2019-02-08 | |||||||||||
Sponsor Name:Polyphor Ltd. | |||||||||||||
Full Title: A multicenter, open-label, sponsor-blinded, randomized, active-controlled, parallel group, pivotal study to evaluate the efficacy, safety, and tolerability of murepavadin given with ertapenem versu... | |||||||||||||
Medical condition: Nosocomial pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) FR (Prematurely Ended) LT (Prematurely Ended) HU (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002542-16 | Sponsor Protocol Number: INSIGHT013 | Start Date*: 2020-09-30 | |||||||||||
Sponsor Name:Office of Sponsored Projects, Regents of the University of Minnesota | |||||||||||||
Full Title: An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the... | |||||||||||||
Medical condition: COVID-19 (SARS-CoV-2) infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) GR (Completed) DK (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004887-74 | Sponsor Protocol Number: AC-065D301 | Start Date*: 2019-08-14 | |||||||||||
Sponsor Name:Actelion Pharmaceuticals Ltd | |||||||||||||
Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Study in Participants with Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag. | |||||||||||||
Medical condition: sarcoidosis-associated pulmonary hypertension (SAPH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) DE (Completed) HU (Prematurely Ended) PL (Completed) ES (Ongoing) BE (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003473-17 | Sponsor Protocol Number: CC-90001-IPF-001 | Start Date*: 2017-09-14 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A Phase 2, 24-Week Randomized, Double-blind, Placebo-Controlled Multicenter Study, With an 80-Week Active Treatment Extension, to Evaluate the Efficacy and Safety of CC-90001 in Subjects with Idiop... | |||||||||||||
Medical condition: IDIOPATHIC PULMONARY FIBROSIS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020376-37 | Sponsor Protocol Number: CP120027.2001 | Start Date*: 2011-02-11 | |||||||||||||||||||||||||||||||
Sponsor Name:Trevena, Inc. | |||||||||||||||||||||||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Adaptive, Ascending Dose-Titration Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Invasive Hemodynamics of TRV120027 in Patient... | |||||||||||||||||||||||||||||||||
Medical condition: Heart failure | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-006054-17 | Sponsor Protocol Number: AC-055B201 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Actelion Pharmaceuticals Ltd. | |||||||||||||
Full Title: A double-blind, randomized, placebo-controlled, multicenter, parallel group study to evaluate the efficacy, safety, and tolerability of macitentan in patients with idiopathic pulmonary fibrosis | |||||||||||||
Medical condition: To evaluate the efficacy, safety, and tolerabilitiy of macitentan in patients with idiopathic pulmonary fibrosis. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) ES (Completed) SI (Completed) SE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-015878-35 | Sponsor Protocol Number: BAY63-2521/14308 | Start Date*: 2010-03-22 | |||||||||||
Sponsor Name:Bayer Healthcare AG | |||||||||||||
Full Title: Randomized, double blind, placebo controlled, parallel group, multi-center study to evaluate the hemodynamic effects of Riociguat (BAY 63-2521) as well as safety and kinetics in patients with pulmo... | |||||||||||||
Medical condition: Pacientes sintomáticos con una hipertensión pulmonar asociada a una disfunción del ventrículo izquierdo (PH-sLVD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) DE (Trial now transitioned) NL (Completed) BE (Completed) AT (Completed) FR (Completed) GB (Completed) IT (Trial now transitioned) DK (Completed) CZ (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
